Antibody-oligonucleotide conjugates (AOCs) approval produces promising progress in targeted means for oncology and genetic disorders. However, approval of the regulator is interrupted by significant chemistry and technical challenges. This article examines obstacles in AOC development, including conjugation complications, stability, and regulatory requirements. This highlights strategies to remove these obstacles and successfully bring AOCS to the market.
https://www.pharmafocuseurope.com/strategy/approval-of-antibody-oligonucleotide-conjugates
Approval of Antibody-Oligonucleotide Conjugates Overcoming Chemistry and Technical Hurdles